KIT D820G

CI-VAR-00000565Explore in graph →NP_000213.1:p.Asp820GlyNM_000222.2:c.2459A>GClinVar 13853 CIViC 1266 rs121913682

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor3
KIT D820G	Imatinib	Predictive	C	Supports Resistance	3	accepted	EID2922 147 patients with advanced, unresectable GISTs were enrolled onto a randomized, phase II clinical study of imatinib (CSTI571-B2222). Specimens from 43 pretreatment and/or imatinib-resistant tumors wer… (full text at CIViC) PMID 16954519 · Heinrich et al., 2006 · Open in CIViC	civic
KIT W557_K558del AND KIT D820G	Ponatinib	Predictive	D	Supports Sensitivity Response	4	submitted	EID7412 Ponatinib possesses potent activity against D820G KIT mutant in preclinical experiments. PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
KIT W557_K558del AND KIT D820G

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13853	Uncertain significance	criteria provided, single submitter	1	MASTOCYTOSIS, SYSTEMIC, SOMATIC; Gastrointestinal stromal tumor; Germinoma	germline/somatic	3	Aug 12, 2022	clinvar